Characterizing Utilization and Outcomes of Digoxin Immune Fab for Digoxin Toxicity

• Egile Nagusiak: Sophia Sheikh (Egilea), Taylor Munson (Egilea), Gerard Garvan (Egilea), Claire Layton (Egilea), Dawn Sollee (Egilea), Colleen Cowdery (Egilea), Alexa Peterson (Egilea), Lindsay Schaack Rothstein (Egilea), Morgan Henson (Egilea), Hayley Gartner (Egilea), Michael Ujhelyi (Egilea)
• Formatua: Liburua
• Argitaratua: Adis, Springer Healthcare, 2024-06-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Abstract Background Digoxin is a widely prescribed drug for congestive heart failure and atrial fibrillation. Digoxin has a narrow therapeutic index and toxicity can develop quite easily. Digoxin immune fab (DIF) is an effective treatment for toxicity, however there are limited studies characterizin...